3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Neoplasm Metastasis
2
Melanoma
2
Breast Neoplasms
2
Brain Neoplasms
2
Thyroid Cancer, Papillary
1
Solid Tumors
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rare Tumour
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Noonan Syndrome 6
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Lymphoma, Large-Cell, Anaplastic
1
Locally Advanced Thyroid Gland Carcinoma
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Lobular
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
Cyclophosphamide
33
fludarabine phosphate
19
Peripheral Blood Stem Cell Transplantation
19
Mycophenolic Acid
17
Whole-Body Irradiation
15
Etoposide
15
Rituximab
14
Tacrolimus
13
Busulfan
12
Vincristine
11
Prednisone
11
Methotrexate
11
Filgrastim
11
Doxorubicin
11
Cyclosporine
11
Radiotherapy
10
Brentuximab Vedotin
10
Antilymphocyte Serum
10
Methylprednisolone
8
Cytarabine
8
Melphalan
7
Cisplatin
6
Ifosfamide
5
Gemcitabine
5
merphos
4
ibritumomab tiuxetan
4
Sirolimus
4
Flow Cytometry
4
Dexamethasone
4
Cyclosporins
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, Large-Cell, Anaplastic
×
entrectinib
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA